CVAC Stock Analysis: Buy, Sell, or Hold?
CVAC - CureVac N.V. Ordinary Shares
$4.66
-0.01 (-0.21%)
▼
HOLD
MODERATE Confidence
Last Updated: January 5, 2026
Earnings: Apr 29, 2026
Get Alerted When CVAC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CVAC shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: CVAC shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: CVAC is currently trading at $4.66, which is considered extended relative to its 30-day fair value range of $4.33 to $4.61.
Technical Outlook: Technically, CVAC is in a strong downtrend. The price is approaching resistance at $4.68. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (5th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $5.38 (+15.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CVAC is in a strong downtrend. The price is approaching resistance at $4.68. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (5th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $5.38 (+15.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$4.33 -
$4.61
Company Quality Score
58/100
(HOLD)
Options IV Signal
5th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
59.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 5th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($5.38)
Fair Price Analysis
30-Day Fair Range
$4.33 -
$4.61
Current vs Fair Value
EXTENDED
Expected Move (7 Days)
±$0.34
(7.2%)
Support & Resistance Levels
Support Level
$4.00
Resistance Level
$4.68
Current Trend
Strong Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
-9.38
Wall Street Target
$5.38
(+15.6%)
Revenue Growth (YoY)
-89.0%
Earnings Growth (YoY)
24.0%
Profit Margin
182.1%
Last updated: February 01, 2026 5:26 PM ET
Data refreshes hourly during market hours. Next update: 6:26 PM
Data refreshes hourly during market hours. Next update: 6:26 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CVAC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$404 | 63 BUY |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 54 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$56 | 59 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$213 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 53 HOLD |
